Management of Unruptured Small Multiple Intracranial Aneurysms in China: A Comparative Effectiveness Analysis Based on Real-World Data

被引:3
|
作者
Chen, Jigang [1 ,2 ]
Tong, Xin [1 ,2 ]
Feng, Xin [3 ]
Peng, Fei [1 ,2 ]
Niu, Hao [1 ,2 ]
Han, Mingyang [4 ]
Liu, Lang [4 ]
Zhao, Yuanli [5 ]
Wang, Daming [3 ]
Pan, Yuesong [6 ,7 ]
Liu, Aihua [1 ,2 ,7 ]
机构
[1] Capital Med Univ, Beijing Neurosurg Inst, Beijing, Peoples R China
[2] Capital Med Univ, Beijing Tiantan Hosp, Dept Intervent Neuroradiol, Beijing, Peoples R China
[3] Beijing Hosp, Natl Ctr Gerontol, Dept Neurosurg, Beijing, Peoples R China
[4] Cent South Univ, Xiangya Hosp 3, Dept Neurosurg, Changsha, Peoples R China
[5] Peking Univ, Peking Univ Int Hosp, Dept Neurosurg, Beijing, Peoples R China
[6] Capital Med Univ, Beijing Tiantan Hosp, Dept Neurol, Beijing, Peoples R China
[7] China Natl Clin Res Ctr Neurol Dis, Beijing, Peoples R China
来源
FRONTIERS IN NEUROLOGY | 2022年 / 12卷
关键词
multiple intracranial aneurysms; small aneurysm; comparative effectiveness analysis; real-world data; endovascular therapy; ENDOVASCULAR TREATMENT; COST-EFFECTIVENESS; PREVALENCE; MORTALITY; RISK; COILING; STROKE; SEX; AGE;
D O I
10.3389/fneur.2021.736127
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
BackgroundUnruptured small aneurysms with a size of <7 mm were often followed conservatively. However, it is unknown whether unruptured small multiple intracranial aneurysms (MIAs) are better to be prophylactically treated or conservatively followed. ObjectiveWe aim to compare the effectiveness of different strategies regarding their management. MethodsA decision-analytic Markov model was built over a entire life cycle. The compared strategies include natural history, treat one aneurysm, treat both aneurysms, annual follow-up, biennial follow-up, and follow-up every 5 years. The inputs for the model were obtained from real-world data and related medical literature. Outcomes were measured in terms of quality-adjusted life-years (QALYs). ResultsTreat both aneurysms had the highest effectiveness of 15.36 QALYs and treat one aneurysm had the second-highest effectiveness of 15.11 QALYs. Probabilistic sensitivity analysis with 10,000 iterations showed that treat both aneurysms and treat one aneurysm were optimal in 67.28 and 17.91% of all cases, respectively. One-way and two-way sensitivity analyses showed that the result was sensitive to the proportion of moderate to severe disability after treating two aneurysms, mortality after treating two aneurysms, proportion of moderate to severe disability after treating one aneurysm, and rupture rate of small growing aneurysm. Either treat both aneurysms or treat one aneurysm would be the optimal strategy under most of the circumstances with the variations of these parameters. ConclusionFor patients with small unruptured MIAs, prophylactic coiling was superior to conservative management and at least one aneurysm should be treated.
引用
收藏
页数:8
相关论文
共 50 条
  • [31] Addressing Posttreatment Selection Bias in Comparative Effectiveness Research, Using Real-World Data and Simulation
    Belviso, Nicholas
    Zhang, Yichi
    Aronow, Herbert D.
    Wyss, Richard
    Barbour, Marilyn
    Kogut, Stephen
    Lawal, Oluwadolapo D.
    Zhan, Si Y.
    Don, Prabhani Kuruppumullage
    Wen, Xuerong
    AMERICAN JOURNAL OF EPIDEMIOLOGY, 2022, 191 (02) : 331 - 340
  • [32] Comparative effectiveness research in COVID-19 using real-world data: methodological considerations
    Read, Stephanie H.
    Khachatryan, Artak
    Chandak, Aastha
    Casciano, Roman
    Hodgkins, Paul
    Haubrich, Richard
    Mozaffari, Essy
    JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2021, 10 (17) : 1259 - 1264
  • [33] Comparative analysis of methods for identifying multimorbidity patterns: a study of 'real-world' data
    Roso-Llorach, Albert
    Violan, Concepcion
    Foguet-Boreu, Quinti
    Rodriguez-Blanco, Teresa
    Pons-Vigues, Mariona
    Pujol-Ribera, Enriqueta
    Valderas, Jose Maria
    BMJ OPEN, 2018, 8 (03):
  • [34] Comparative effectiveness analysis between entrectinib clinical trial and crizotinib real-world data in ROS1+ NSCLC
    Doebele, Robert C.
    Perez, Laura
    Trinh, Huong
    Martinec, Michael
    Martina, Reynaldo
    Riehl, Todd
    Krebs, Matthew G.
    Meropol, Neal J.
    Wong, William B.
    Crane, Gracy
    JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2021, 10 (17) : 1271 - 1282
  • [35] ECONOMIC IMPACT OF INNOVATIVE DRUGS FOR MULTIPLE SCLEROSIS: A REAL-WORLD DATA ANALYSIS
    Buigues-Pastor, L.
    Uso-Talamantes, R.
    Alos-Alminana, M.
    VALUE IN HEALTH, 2022, 25 (01) : S259 - S259
  • [36] Real-world pharmacovigilance of ofatumumab in multiple sclerosis: a comprehensive FAERS data analysis
    Chen, Hui
    FRONTIERS IN PHARMACOLOGY, 2025, 15
  • [37] Predicting the intervention threshold for initiating osteoporosis treatment among postmenopausal women in China: a cost-effectiveness analysis based on real-world data
    L. Cui
    T. He
    Y. Jiang
    M. Li
    O. Wang
    R. Jiajue
    Y. Chi
    Q. Xu
    X. Xing
    W. Xia
    Osteoporosis International, 2020, 31 : 307 - 316
  • [38] Predicting the intervention threshold for initiating osteoporosis treatment among postmenopausal women in China: a cost-effectiveness analysis based on real-world data
    Cui, L.
    He, T.
    Jiang, Y.
    Li, M.
    Wang, O.
    Jiajue, R.
    Chi, Y.
    Xu, Q.
    Xing, X.
    Xia, W.
    OSTEOPOROSIS INTERNATIONAL, 2020, 31 (02) : 307 - 316
  • [39] EVALUATING THE COST-EFFECTIVENESS OF METFORMIN IN PREDIABETES MANAGEMENT: A MARKOV MODEL ANALYSIS COMBINING CLINICAL AND REAL-WORLD DATA
    Liu, Y.
    Zhu, B.
    Zhu, L.
    Jin, C.
    VALUE IN HEALTH, 2024, 27 (12)
  • [40] "Real-world data analysis" in disease management such as hypertension: Has the time come?
    Edwards, Elizabeth
    DiPette, Donald J.
    JOURNAL OF CLINICAL HYPERTENSION, 2019, 21 (05): : 635 - 637